GoldenGolden
Advanced Search
SK Bioscience

SK Bioscience

SK Bioscience is a subsidiary of South Korean conglomerate SK Group and focuses on the discovery and production of vaccines. It was established in 2018 and is located in Seongnam, South Korean.

SK Bioscience is a subsidiary of South Korean conglomerate SK Group and focuses on the discovery and production of vaccines. The vaccine research and production company was spun out from SK Chemicals in 2018.

Technology

SK Bioscience has technology capabilities in R&D and manufacturing.

Its research and development technologies include suspension cell culture, conjugation technology, and reverse genetic technologies. Its main production facility L HOUSE, located in Andong Gyeongbuk Bio Industrial Complex, uses single-use bags in its bioreactor, rather than conventional stainless steel tanks.

Research History

In 2006, SK Bioscience began research for a self-developed vaccine. In 2014, the company signed an agreement with Sanofi Pasteur SA for joint R&D and the sale of next-generation’s pneumococcal conjugate vaccine (PCV).

It also developed other vaccine products, including Korea’s first cell culture-derived trivalent influenza vaccine (2014) and the world’s first cell culture-derived quadrivalent influenza vaccine (2015).

It has acquired marketing approval for “SKYZOSTER”, a shingles vaccine (2017), and SKY Varicella, a varicella vaccine (2018).

COVID-19

The company researched and developed a medical solution for COVID-19 using a monoclonal antibody treatment candidate. The company has a manufacturing plant that can produce vaccines for the virus once they have been approved by the appropriate governing bodies.

Timeline

March 23, 2020
SK Bioscience starts animal trial of COVID-19 vaccine
2018
Established SK Bioscience
2017
Signed an agreement with international organization PATH to develop and produce pediatric enteritis vaccine for developing countries
2017
Launched Sky Zoster Inj., world’s second shingles vaccine
2017
Gained approval for SKYPNEUMO, the first domestically produced PCV13 vaccine
2016
Launched SKYCellflu, Korea’s first trivalent cell culture-derived influenza vaccine
2016
Launched SKYCellflu Quadrivalent, world’s first quadrivalent cell culture-derived influenza vaccine
2015
Acquired KGMP for L HOUSE (Andong Vaccine Plant)
2014
Established strategic partnership with Sanofi Pasteur for co-development of next-generation’s pneumococcal conjugate vaccine
2013
Established partnership with IVI (International Vaccine Institute) to collaborate on the development of a new typhoid conjugate vaccine
Page 1 of 2

People

Name
Role
LinkedIn

Further reading

Title
Author
Link
Type
Date

SK Bioscience starts animal trial of COVID-19 vaccine - Korea Biomedical Review

Lee Han-soo

Web

March 23, 2020

SK Bioscience to expand vaccine production facility - Korea Biomedical Review

Marian Chu

Web

July 18, 2018

Documentaries, videos and podcasts

Title
Date
Link

Companies

Company
CEO
Location
Products/Services

News

Title
Author
Date
Publisher
Description
Joyce Lee
March 8, 2021
DealStreetAsia
South Korea is set for a busy IPO market this year as firms take advantage of robust retail demand.
Reuters
November 27, 2020
DealStreetAsia
SK Bioscience has hired NH Investment & Securities as lead manager.

References

Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.